Further steps in the clinical development of FOL-005 is to continue with phase II and phase III trials.
In parallel to our clinical development of FOL-005 we are also developing a new user friendly formulation. In the summer of 2018 this work resulted in the selection of a topical formulation which we filed a patent application for in spring 2019. The formulation will be applied on the scalp and has shown good hair stimulating effect in an animal model. If the patent application is approved, the protection of FOL-005 will be extended with 8 years. The next step is to test the formulation in a clinical phase II trial on alopecia patients, which is planned to start in the end of 2019/beginning of 2020. The final product will now be tested in phase II trials, followed by phase III trials before being approved and launched on the market.